These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 11336111)

  • 1. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
    Lu HR; Vlaminckx E; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2005; 52(1):90-105. PubMed ID: 15978848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
    Eckardt L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization.
    Terrar DA; Wilson CM; Graham SG; Bryant SM; Heath BM
    J Pharmacol Toxicol Methods; 2007; 56(2):171-85. PubMed ID: 17596973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and D, L-sotalol.
    Limberis JT; McDermott JS; Salmen HJ; Su Z; Mikhail A; Green JR; Cox BF; Gintant GA; Martin RL
    J Pharmacol Toxicol Methods; 2007; 56(1):11-7. PubMed ID: 17350293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
    Thomsen MB; Beekman JD; Attevelt NJ; Takahara A; Sugiyama A; Chiba K; Vos MA
    Br J Pharmacol; 2006 Dec; 149(8):1039-48. PubMed ID: 17088870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
    Champeroux P; Viaud K; El Amrani AI; Fowler JS; Martel E; Le Guennec JY; Richard S
    Br J Pharmacol; 2005 Feb; 144(3):376-85. PubMed ID: 15655517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C; Sterneberg M; Kochhäuser S; Dechering DG; Fehr M; Eckardt L; Frommeyer G
    Europace; 2018 Oct; 20(10):1699-1706. PubMed ID: 29377987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
    Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
    J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability.
    Wisialowski T; Crimin K; Engtrakul J; O'Donnell J; Fermini B; Fossa AA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):352-9. PubMed ID: 16614168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
    Yan GX; Wu Y; Liu T; Wang J; Marinchak RA; Kowey PR
    Circulation; 2001 Jun; 103(23):2851-6. PubMed ID: 11401944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
    Roden DM
    Eur Heart J; 1993 Nov; 14 Suppl H():56-61. PubMed ID: 8293755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine.
    Fazekas T; Krassói I; Lengyel C; Varró A; Papp JG
    Pacing Clin Electrophysiol; 1998 Jan; 21(1 Pt 2):147-50. PubMed ID: 9474662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.